Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Trastuzumab deruxtecan (gastric cancer) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A23-08
Last updated

Report documents

  1. Extract of dossier assessment

    Trastuzumab deruxtecan (gastric cancer) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 452 kB, EN, not accessible
    Download file : Extract of dossier assessment (PDF document, 452 kB, EN, not accessible)

  2. Dossier assessment

    Trastuzumab deruxtecan (gastric cancer) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 606 kB, DE, not accessible
    Download file : Dossier assessment (PDF document, 606 kB, DE, not accessible)

Dossier assessment

Indication:

Adults with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma

Result of dossier assessment:
  • Patients who have received 1 prior trastuzumab-based regimen in first-line therapy: added benefit not proven
  • Patients who have received at least 2 prior regimens, including trastuzumab: added benefit not proven

Project details

Project no.
A23-08
Commission
Commission awarded on 01.02.2023 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-81
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-80
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-07
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-54
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Trastuzumab deruxtecan (gastric or gastroesophageal junction adenocarcinoma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-128
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Trastuzumab deruxtecan (NSCLC) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-115
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page